Price adjustment be spotted crux of vigorous pharmaceutical companies - pharmaceutical companies - pharmaceutical industries
The current environment, some pharmaceutical companies to enhance the quality of the driving force for the lack of consciousness. First of all, talk about it from drug prices. For the suppression Pharmacy Price, NDRC launched 25 times in recent years, a wide range of price adjustment, but "your doctor" issue has not been significantly alleviated, there is still good value many of the early termination of the life cycle of drugs on the market some of the life-saving cheap old Drugs not a trace repeatedly appeared in press. Some pharmaceutical companies produce drugs, especially low-cost drugs, low-limit feeding, cutting corners, shoddy materials.
Second, although the pace of the NDRC price adjustment slowed since last year, but vigorous Tender Procurement continues to promote, in some places on the tender process Drug Quality Assessment mechanisms are still not perfect enough. As we all know, an enterprise through a GMP Certification , Drug obtained approval, produced it passed the test, the product is legally qualified. If dozens or even hundreds of such products also participate in the tender, how to assess their quality? I am afraid instead of tender documents can be easily adopted by the Commission under the tender conclusion. When assessing the quality of formality, the price of the importance of the prominent, and the products homogeneous severe cases, some places more like a wide range of current tender price reduction continuation of the policy. Plus the current implementation of all the pharmaceutical companies have adopted in the 2004 GMP, the failure to do overall planning and massive debt, thus Kangshang heavy burden of enterprises, is to bear the brunt of payment, sellers quickly, make money loan repayment, some enterprises so long also had a "quality by inspection is like, almost on the line of raw materials" mentality, which is not normal.
In fact, the countries have already seen crux of the problem, re-registration approval, the new revised Pharmacopoeia Encourage enterprises to improve quality standards, the new emphasis on software development and GMP production process, are the crux of the next move should.
The one hand, government policies to promote, on the other hand, enterprises can not remain indifferent to improve drug quality should become the industry's conscious action. This is a big challenge that requires multi-sectoral synergies, which, I have the following recommendations:
First, the original high-quality and favorable price, single price, Traditional Chinese medicine Protection, patents, original research, the first simulation and other varieties, to the tender, the price of a plus; Second, pharmaceutical tender areas, particularly for essential drugs in the tender, which the "quality points" to increase through the new GMP fraction of the weight, to encourage drug preparing a new certification enterprise. In the Pharmaceutical approval for the record, Medicare , Concerning selection of essential medicines and other key areas of market access, together with encouragement; Third, the tender, the price adjustment to encourage enterprises to enhance their internal control standards, increase the detection of targets, especially traditional Chinese medicine.
I am a professional writer from China Computer Parts, which contains a great deal of information about puff pastry recipe , puff pastry recipes, welcome to visit!
